scholarly journals 1207: REDUCING CAUTIS WITH A NOVEL CATHETER TECHNOLOGY IN THE ICU

2021 ◽  
Vol 50 (1) ◽  
pp. 603-603
Author(s):  
Connie Van ◽  
Jolene Smeltzer ◽  
Julie Che
Keyword(s):  
Catheter Technology

Comparative study of intracranial access in thrombectomy using next generation 0.088 inch guide catheter technology

2021 ◽  
pp. neurintsurg-2021-017341
Author(s):  
Devin V Bageac ◽  
Blake S Gershon ◽  
Jan Vargas ◽  
Maxim Mokin ◽  
Zeguang Ren ◽  
...  
Keyword(s):  
Primary Outcome ◽  
Primary Outcome Measure ◽  
Secondary Outcome ◽  
Control Group ◽  
Anterior Circulation ◽  
Guide Catheter ◽  
Catheter Failure ◽  
Catheter Technology ◽  
Intracranial Vasculature

BackgroundMost conventional 0.088 inch guide catheters cannot safely navigate intracranial vasculature. The objective of this study is to evaluate the safety of stroke thrombectomy using a novel 0.088 inch guide catheter designed for intracranial navigation.MethodsThis is a multicenter retrospective study, which included patients over 18 years old who underwent thrombectomy for anterior circulation large vessel occlusions. Technical outcomes for patients treated using the TracStar Large Distal Platform (TracStar LDP) or earlier generation TRX LDP were compared with a matched cohort of patients treated with other commonly used guide catheters. The primary outcome measure was device-related complications. Secondary outcome measures included guide catheter failure and time between groin puncture and clot engagement.ResultsEach study arm included 45 patients. The TracStar group was non-inferior to the control group with regard to device-related complications (6.8% vs 8.9%), and the average time to clot engagement was 8.89 min shorter (14.29 vs 23.18 min; p=0.0017). There were no statistically significant differences with regard to other technical outcomes, including time to recanalization (modified Thrombolysis In Cerebral Infarction (mTICI) ≥2B). The TracStar was successfully advanced into the intracranial internal carotid artery in 33 cases (73.33%); in three cases (6.67%), it was swapped for an alternate catheter. Successful reperfusion (mTICI 2B-3) was achieved in 95.56% of cases. Ninety-day follow-up data were available for 86.67% of patients, among whom 46.15% had an modified Rankin Score of 0–2%, and 10.26% were deceased.ConclusionsTracstar LDP is safe for use during stroke thrombectomy and was associated with decreased time to clot engagement. Intracranial access was regularly achieved.

Catheter-Based Dilation of the Sinus Ostia: Initial Safety and Feasibility Analysis in a Cadaver Model

2006 ◽  
Vol 20 (3) ◽  
pp. 290-294 ◽  
Author(s):  
William E. Bolger ◽  
Winston C. Vaughan
Keyword(s):  
Ct Scan ◽  
Safety Information ◽  
Balloon Catheter ◽  
Ease Of Use ◽  
Sinus Surgery ◽  
Human Cadaver ◽  
Invasive Treatment ◽  
Urologic Diseases ◽  
Anatomic Dissection ◽  
Catheter Technology

Background Over the past 20 years, many patients have benefited from endoscopic sinus surgery and its ability to relieve sinus obstruction. However, problems still occur with surgery, thereby leaving room for innovation. Recently, catheter-based technology has provided new options for treating cardiac, vascular, and urologic diseases. We speculated that catheter technology also might offer new treatment options for sinusitis patients. The purpose of this investigation was to explore the feasibility and safety of catheter-based technology to relieve sinus ostial obstruction. Methods Anatomic models and human cadaver specimens were used initially to design and iterate catheters to open sinus ostial drainage pathways. Thereafter, the safety of balloon-catheter dilation was evaluated in six human cadaver heads. CT scan obtained before and after catheter ostial dilation was analyzed for evidence of catheter-induced trauma. Dilated ostia also were examined by endoscopy and gross anatomic dissection for unwanted catheter-induced trauma. Results Catheters successfully dilated 31 of 31 ostia, including 9 maxillary, 11 sphenoid, and 11 frontal ostia/recesses. CT scan, endoscopy, and gross anatomic dissection revealed that such dilation did not cause trauma to surrounding structures such as the orbit or skull base. Mucosal trauma imparted by catheter dilation appeared to be less than that normally seen with standard endoscopic instruments. Conclusion This initial study suggests that catheter technology can be used to dilate sinus ostia safely. Mucosal preservation and ease of use make catheters an attractive minimally invasive treatment strategy. Additional testing in patients is indicated to gain additional safety information and to explore the usefulness of catheter-based technology.

Laser

2010 ◽  
pp. 568-585
Author(s):  
Peter O’Kane ◽  
Simon Redwood
Keyword(s):  
Balloon Angioplasty ◽  
Clinical Case ◽  
Laser Energy ◽  
Medical Application ◽  
Laser Angioplasty ◽  
Case Examples ◽  
Tissue Interactions ◽  
Percutaneous Coronary ◽  
Catheter Technology ◽  
Carbon Dioxide Co2

The first medical application of laser was reported by Dr Leon Goldman who, in 1962, reported the use of ruby and carbon dioxide (CO2) lasers in dermatology. In cardiovascular disease, early laser use was confined to cadaver vessels, animal models, and arteries located in freshly amputated limbs, until eventually work progressed to the use of laser energy to salvage an ischaemic limb in 1984. The concept of using laser to remove atherosclerotic material in coronary arteries developed as an alternative strategy to simply modifying the shape of an obstructed lumen as occurs with simple balloon angioplasty. Expectations grew that this new biomedical technology may overcome the low success rate and high complication rate of lesions considered non-ideal for balloon angioplasty. However, initial successful reports could not be replicated. Furthermore, underdeveloped catheter technology and limited appreciation of laser/tissue interactions meant that a cure for restenosis was not in fact discovered and laser coronary angioplasty became isolated to only a few centres in the world. However, more recently with advancement in both catheter technology and technique, excimer coronary laser angioplasty (ELCA) has been rediscovered for use in specific subsets of percutaneous coronary interventions (PCIs). This chapter outlines the basic principles of ELCA and important practical aspects for using the device in contemporary PCI. A discussion of the current indications for clinical use follows and these are highlighted by clinical case examples.

In reference to Balloon catheter technology in rhinology: Reviewing the evidence

2012 ◽  
Vol 122 (2) ◽  
pp. 480-481
Author(s):  
Thomas A. Tami ◽  
Jeffrey Cutler ◽  
James Atkins
Keyword(s):  
Balloon Catheter ◽  
Catheter Technology

scholarly journals Balloon Catheter Technology in Rhinology: Reviewing the Evidence

2011 ◽  
Vol 145 (2_suppl) ◽  
pp. P34-P35
Author(s):  
Pete S. Batra ◽  
Bradley F. Marple ◽  
Matthew W. Ryan ◽  
Raj Sindwani
Keyword(s):  
Balloon Catheter ◽  
Catheter Technology

scholarly journals 810. Resistance to the Minocycline-Rifampin-Chlorhexidine (MRCH) combination does not emerge in biofilms of Tetracycline and Rifampin resistant bacteria grown on MRCH catheters depleted below antimicrobially effective concentrations

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S448-S448
Author(s):  
Bahgat Gerges ◽  
Joel Rosenblatt ◽  
Y-Lan Truong ◽  
Ruth Reitzel ◽  
Ray Y Hachem ◽  
...  
Keyword(s):  
Bloodstream Infections ◽  
Cancer Center ◽  
Resistant Bacteria ◽  
Material Support ◽  
University Of Texas ◽  
Cook Medical ◽  
Catheter Technology ◽  
Md Anderson ◽  
The University

Abstract Background Central Line Associated Bloodstream Infections (CLABSIs) remain a significant medical problem for critically ill cancer patients who required catheters for extended durations. Minocycline (M) -Rifampin (R) loaded catheters have shown the greatest impact on reducing CLABSIs; however, there is a risk for developing antibiotic resistant organisms when exposed to catheters whose concentration becomes depleted below antimicrobially effective levels due to extended indwells. Chlorhexidine (CH) and M-R combination catheters (MRCH) have been proposed as a next generation catheter with improved performance. Here we studied whether bacteria that were Tetracycline and Rifampin resistant became resistant to MRCH when allowed to form biofilms on MRCH catheters depleted below antimicrobially effective MRCH concentrations. Methods Minimum inhibitory concentrations (MICs) of Tetracycline and/or Rifampin resistant stock isolates were measured by standard microbroth dilution methods. MRCH catheters were depleted to below antimicrobially effective concentrations by soaking in serum for 6 weeks. The resistant bacteria were then allowed to form biofilm for 24 hrs on the depleted catheters in broth. Following 24 hour incubation the adherent (breakthrough) bacteria were removed by sonication and MICs were remeasured. The same organisms grown on non-antimicrobial catheters were used as controls. Results MICs (ug/mL) of the organisms against each agent and the combination are tabulated below: MICs (ug/mL) of the organisms against each agent and the combination Conclusion The M and R resistant bacteria did not develop in vitro resistance to the MRCH combination after forming biofilms on MRCH catheters depleted below antimicrobially effective concentrations. Disclosures Joel Rosenblatt, PhD, Cook Medical (Shareholder, Other Financial or Material Support, Inventor of the MRCH catheter technology which is owned by the University of Texas MD Anderson Cancer Center and has been licensed to Cook Medical)Novel Anti-Infective Technologies (Shareholder, Other Financial or Material Support, Inventor of the MRCH catheter technology which is owned by the University of Texas MD Anderson Cancer Center and has been licensed to Cook Medical) Issam I. Raad, MD, Citius (Other Financial or Material Support, Ownership interest)Cook Medical (Grant/Research Support)Inventive Protocol (Other Financial or Material Support, Ownership interest)Novel Anti-Infective Technologies (Shareholder, Other Financial or Material Support, Ownership interest)

scholarly journals 24 Hour Assessment of Pancolonic Motor Activity in Health Using Solid-State Catheter Technology: Comparison With Traditional Water-Perfused Catheters

2011 ◽  
Vol 140 (5) ◽  
pp. S-871
Author(s):  
Sahar Mohammed ◽  
Natalia Zarate ◽  
Sean L. Preston ◽  
Peter J. Lunniss ◽  
Philip G. Dinning ◽  
...  
Keyword(s):  
Solid State ◽  
Motor Activity ◽  
Catheter Technology ◽  
Technology Comparison ◽  
Perfused Catheters

scholarly journals Impact of Micro-, Mini- and Multi-Electrode Mapping on Ventricular Substrate Characterisation

2020 ◽  
Vol 9 (3) ◽  
pp. 128-135
Author(s):  
Benjamin Berte ◽  
Katja Zeppenfeld ◽  
Roderick Tung
Keyword(s):  
Ventricular Tachycardia ◽  
Cardiac Arrhythmias ◽  
Signal To Noise Ratio ◽  
Near Field ◽  
Field Of View ◽  
Ablation Catheter ◽  
Signal To Noise ◽  
Voltage Mapping ◽  
Practice Variations ◽  
Catheter Technology

Accurate substrate characterisation may improve the evolving understanding and treatment of cardiac arrhythmias. During substrate-based ablation techniques, wide practice variations exist with mapping via dedicated multi-electrode catheter or conventional ablation catheters. Recently, newer ablation catheter technology with embedded mapping electrodes have been introduced. This article focuses on the general misconceptions of voltage mapping and more specific differences in unipolar and bipolar signal morphology, field of view, signal-to-noise ratio, mapping capabilities (density and resolution), catheter-specific voltage thresholds and impact of micro-, mini- and multi-electrodes for substrate mapping. Efficiency and cost-effectiveness of different catheter types are discussed. Increasing sampling density with smaller electrodes allows for higher resolution with a greater likelihood to record near-field electrical information. These advances may help to further improve our mechanistic understanding of the correlation between substrate and ventricular tachycardia, as well as macro-reentry arrhythmia in humans.

Sign in / Sign up

Export Citation Format

Share Document